Editorial: First Among Equals-Not for Either Infliximab or Adalimumab in Crohn's Disease-Yet
Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14549
Full Text
Open PDFAbstract
Available in full text
Date
March 25, 2018
Authors
Publisher
Wiley